Pfizer CentreOne, Pfizer's combined contract manufacturing organization, has officially launched as a contract manufacturing organization focused on active pharmaceutical ingredient (API) synthesis and sterile injectables fill-finish. The company was born of the union of Pfizer CentreSource, a provider of specialty APIs, and Hospira One 2 One, a sterile-injectables CMO and part of Hospira, which Pfizer acquired in September 2015.

“As a combined organization, we've brought together the best of our manufacturing capabilities to provide a wider array of services and technologies to our biopharmaceutical partners,” said Peter Stevenson, vice president and general manager of Pfizer CentreOne. “Although Pfizer CentreOne is a new name, we've been providing contract manufacturing services for more than 40 years and are committed to further growing our business.” That commitment is reflected by Pfizer's pledge to reserve capacity for Pfizer CentreOne partner drugs across its dedicated facilities. If you're our biopharma partner, we're dedicated to you for the long haul.”

Pfizer CentreOne is aligned into two primary areas of expertise: API and drug product. Specific focuses are: small-molecule steroid and hormone intermediates and APIs; custom small-molecule API synthesis; and sterile injectables fill-finish.

Pfizer CentreOne is a self-contained CMO embedded within Pfizer, with its own dedicated team that reports through Pfizer's commercial organization.

Source: Pfizer CentreOne